Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of drug-induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance. Several risk factors have been identified for drug-induced cholestasis, including older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug-induced cholestatic liver injury. ( 2017;1:726-735).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678916PMC
http://dx.doi.org/10.1002/hep4.1088DOI Listing

Publication Analysis

Top Keywords

drug-induced cholestasis
12
cholestasis cholestatic
8
liver injury
8
clinical presentation
8
associated condition
8
cholestatic dili
8
risk factors
8
drug-induced
5
cholestatic
5
cholestatic drug-induced
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!